Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Scholar Rock said it resubmitted the marketing authorisation application for apitegromab to the European Medicines Agency for children and adults with spinal muscular atrophy. The company said the filing includes an alternate fill-finish facility and it expects a CHMP opinion in the first half of 2027.
Scholar Rock (SRRK) has resubmitted its apitegromab marketing authorisation application (MAA) to the European Medicines Agency (EMA) for treatment of children and adults with spinal muscular atrophy (SMA).
Scholar Rock (SRRK) said it has resubmitted its marketing authorisation application for apitegromab to the European Medicines Agency (EMA) for treatment of children and adults with spinal muscular atrophy (SMA).